Literature DB >> 18710819

Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest.

Sayaka Yoshiba1, Daisuke Ito, Tatsuhito Nagumo, Tatsuo Shirota, Masashi Hatori, Satoru Shintani.   

Abstract

Malignant tumors are exposed to various levels of hypoxic condition in vivo. It has been known that tumor cells under hypoxia are resistant to chemotherapies. To clarify the mechanism of the hypoxia-induced chemoresistance, we evaluated the effects of hypoxia on the resistance of oral squamous cell carcinoma (OSCC) cell lines to 5-fluorouracil (5-FU). OSCC cells were divided to two groups by the proliferation activity under hypoxic condition; hypoxia-resistant (HR) and hypoxia-sensitive (HS) cells. Growth of HS cells were inhibited by hypoxia and introduced to G(1) arrest in cell cycle. 5-FU effect on HS cell viability was markedly reduced in hypoxic condition without an induction of chemoresistant related protein, P-glycoprotein. However, proliferation, cell cycle, and 5-FU sensitivity of HR cells were not affected by hypoxia. Hypoxia-inducible factor (HIF)-1alpha was induced by hypoxia in all OSCC cell lines, but diminished in HS cells within 48h. Expression of p21 and p27 was strongly augmented and CyclinD expression was reduced by hypoxia in HS cells. However, the expression of these proteins was constitutive in HR cells during 48h hypoxic culture. Phosphorylation of mammalian target of rapamycin (mTOR) was reduced by hypoxia in HS cells. From these findings, we concluded that HS OSCC cells acquire 5-FU resistance under hypoxia by G(1)/S transition through an upregulation of cell cycle inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18710819     DOI: 10.1016/j.oraloncology.2008.04.002

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  26 in total

1.  Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells.

Authors:  Jing-Qiu Li; Xian Wu; Lu Gan; Xiang-Liang Yang; Ze-Hong Miao
Journal:  Acta Pharmacol Sin       Date:  2017-07-10       Impact factor: 6.150

2.  Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma.

Authors:  Tomofumi Naruse; Souichi Yanamoto; Shin-ichi Yamada; Satoshi Rokutanda; Akiko Kawakita; Goro Kawasaki; Masahiro Umeda
Journal:  Pathol Oncol Res       Date:  2015-02-15       Impact factor: 3.201

3.  Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma.

Authors:  Jun Sato; Yoshimasa Kitagawa; Yutaka Yamazaki; Hironobu Hata; Takuya Asaka; Masaaki Miyakoshi; Shozo Okamoto; Tohru Shiga; Masanobu Shindoh; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-28       Impact factor: 9.236

4.  Chemosensitization of cancer cells via gold nanoparticle-induced cell cycle regulation.

Authors:  Megan A Mackey; Mostafa A El-Sayed
Journal:  Photochem Photobiol       Date:  2014-02-11       Impact factor: 3.421

5.  Effect of multidrug resistance 1/P-glycoprotein on the hypoxia-induced multidrug resistance of human laryngeal cancer cells.

Authors:  Dawei Li; Liang Zhou; Jiameng Huang; Xiyan Xiao
Journal:  Oncol Lett       Date:  2016-06-17       Impact factor: 2.967

6.  Hypoxia-induced autophagy contributes to radioresistance via c-Jun-mediated Beclin1 expression in lung cancer cells.

Authors:  Yan-Mei Zou; Guang-Yuan Hu; Xue-Qi Zhao; Tao Lu; Feng Zhu; Shi-Ying Yu; Hua Xiong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-10-16

7.  DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.

Authors:  Kathryn M Camacho; Stefano Menegatti; Douglas R Vogus; Anusha Pusuluri; Zoë Fuchs; Maria Jarvis; Michael Zakrewsky; Michael A Evans; Renwei Chen; Samir Mitragotri
Journal:  J Control Release       Date:  2016-03-24       Impact factor: 9.776

8.  The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells.

Authors:  Dongming Liang; Yuanyuan Ma; Jian Liu; Claes Goran Trope; Ruth Holm; Jahn M Nesland; Zhenhe Suo
Journal:  BMC Cancer       Date:  2012-05-29       Impact factor: 4.430

9.  Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer.

Authors:  Becky A S Bibby; Niluja Thiruthaneeswaran; Lingjian Yang; Ronnie R Pereira; Elisabet More; Darragh G McArt; Paul O'Reilly; Robert G Bristow; Kaye J Williams; Ananya Choudhury; Catharine M L West
Journal:  BMC Urol       Date:  2021-07-01       Impact factor: 2.264

10.  Transcutaneous Carbon Dioxide Decreases Immunosuppressive Factors in Squamous Cell Carcinoma In Vivo.

Authors:  Nanae Yatagai; Takumi Hasegawa; Rika Amano; Izumi Saito; Satomi Arimoto; Daisuke Takeda; Yasumasa Kakei; Masaya Akashi
Journal:  Biomed Res Int       Date:  2021-07-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.